Spots Global Cancer Trial Database for Moxifloxacin in Adjuvant Treatment of Patients With Operable Breast Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Moxifloxacin in Adjuvant Treatment of Patients With Operable Breast Cancer

Official Title: A Multicenter, Placebo-Controlled, Phase III Trial of Standard Adjuvant Chemotherapy Plus Moxifloxacin in Operable Breast Cancer

Study ID: NCT05114720

Conditions

Breast Cancer

Interventions

standard adjuvant chemotherapy plus moxifloxacin

standard adjuvant chemotherapy plus placebo

Study Description

Brief Summary: The primary objective of this study is to compare disease-free survival (DFS) of patients with operable breast cancer randomised to treatment with standard adjuvant chemotherapy plus moxifloxacin or placebo.

Detailed Description: This is a multicenter, randomised, double-blind, placebo-controlled, phase 3 clinical trial. The main purposes of this study are to examine the efficacy and safety of standard adjuvant chemotherapy plus moxifloxacin or placebo as care for patients with operable breast cancer. This study is designed to recruit up to 520 subjects.